Loading the section…

CSTL: financial statements from SEC — TradeAlmanac

CSTL

Castle Biosciences, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Revenue	84M	83M	86M	88M	86M	87M
Cost of revenue	21M	19M	18M	16M	16M	15M
Research and development	14M	13M	13M	13M	12M	14M
Selling, general and administrative	65M	56M	58M	59M	50M	51M
Operating income	−18M	−7M	−4M	−28M	5M	5M
Income tax	109,000	115,000	−5M	−423,000	6M	−1M
Net income	−15M	−501,000	5M	−26M	2M	9M
Earnings per share	−0.49	−0.02	0.16	−0.90	0.08	0.32
Earnings per share, diluted	−0.49	−0.02	0.15	−0.90	0.08	0.31
Weighted average shares	30M	29M	29M	29M	28M	28M
Weighted average shares, diluted	30M	29M	30M	29M	29M	29M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	64M	117M	86M	82M	90M	120M	95M	86M
Short-term investments	198M	183M	202M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	−22M	−6M
Depreciation and amortisation	4M	30M
Share-based compensation	10M	11M
Capital expenditure	12M	5M
Investing cash flow	−26M	−22M
Financing cash flow	−5M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator